Amber De Bleeckere

 Amber De Bleeckere

 Amber de Bleeckere

Laboratory of Pharmaceutical Microbiology (LPM)
Universiteit Gent
Ottergemsesteenweg 460
B-9000 Gent - Belgium

Tel: 32 - (0) 9 264 80 93
Fax: 32 - (0) 9 264 81 95


list of publications

Amber De Bleeckere graduated as at Ghent University in June 2019. He is currently working as a PhD student in the Laboratory of Pharmaceutical Microbiology.

Bacteria can form biofilms that will serve as a protective barrier which might give an decreased susceptibility to abiotic agents. The biofilm can be formed on both biotic and abiotic surfaces. Due to the protective property of biofilms, biofilm infections are more difficult to treat and might lead to chronic infections. Therefore, scientists are keened to find methods that can disrupt biofilms.

One approach that can be used is a mechanical disruption. Such a mechanical disruption might be created with vapor nanobubbles (VNBs). To create VNBs, gold nanoparticles are added to biofilms which will penetrate the biofilm. By an irradiation with a laser over a short time span, VNBs will be created around the gold particles. These VNBs will induce a mechanical expansion and will lead to disruption of a biofilm.

The general focus of Jaspers research will be on biofilm dispersion. First a basic approach will be used to determine the different stages of biofilm development. This will be determined for different species, including some species of the genera Burkholderia and Pseudomonas, in different biofilm model systems. When more insight is gained in active dispersion, the focus will deflect towards VNB induced dispersion. First, the differences between viability of bacteria will be determined after a VNB treatment. Next, the differences in gene exprression between active and passive dispersion, sessile and planktonic bacteria will be investigated. For this transcriptiomic approach, next generation sequencing techniques (illumina) will be used. In a last phase, the gained transcriptomic data will be validated by mutagenesis. This validation will give more insight in biofilms development and the dispersion of biofilms, which might eventually lead to the development of new therapeutics that can induce biofilm dispersion.